Secondary study of data from the CANTAM study in Gabon, which evaluated the safety and efficacy of pyronaridine-artesunate in a real-world setting. 2,082 patients (adults and children weighing ≥ 5 kg) with uncomplicated malaria were included between June 2017 and March 2019. Of 1,687 patients in the per-protocol analysis, 129 (7.7%) experienced recurrence and 22 (1.3%) recrudescence. Repeated malaria episodes accounted for 17.4% of cases. Advanced age was associated with a lower risk of recurrence and recrudescence. Prior malaria increased the risk of recurrence and recrudescence, especially in young children. Targeted follow-up is needed for patients at higher risk of treatment failure.


